Hyperglycaemia (HG) decreases intracellular tetrahydrobiopterin (BH 4 ) concentrations, and this action may contribute to injury during myocardial ischaemia and reperfusion. We investigated whether increased BH 4 by cardiomyocyte-specific overexpression of the GTP cyclohydrolase (GTPCH) 1 gene rescues myocardial and mitochondrial protection by ischaemic preconditioning (IPC) during HG through a nitric oxide (NO)-dependent pathway.
Introduction
Hyperglycaemia (HG) commonly occurs in patients with acute myocardial infarction and is associated with poor prognosis and increased mortality. 1 The mechanisms responsible for increased morbidity and mortality during HG are unclear; however, disruption of endogenous cardioprotective pathways is likely. For example, ischaemic preconditioning (IPC) is a phenomenon in which brief periods of myocardial ischaemia and reperfusion protect the heart against infarction during a subsequent more prolonged period of coronary artery occlusion. 2 We and others have shown that transient HG abolishes the cardioprotective effects of IPC in dogs, rabbits, and in humans, 3 -6 although the specific mechanisms involved have not been completely elucidated.
The present study was designed to address the hypothesis that tetrahydrobiopterin (BH 4 ) is a key mediator of IPC that is adversely modulated by HG, but cardioprotection can be restored by a genetic approach to enhancing BH 4 synthesis with cardiomyocyte-targeted overexpression of GTP cyclohydrolase (GTPCH) 1.
BH 4 is a reduced unconjugated pterin and essential cofactor that regulates nitric oxide (NO) synthesis by NO synthases (NOS) expressed within cardiomyocytes and coronary vasculature and is an important determinant of NO-dependent signalling. 7, 8 Increased expression of GTPCH-1, the first and rate-limiting enzyme for the de novo synthesis of BH 4 , might be a strategy to improve NOS function during HG and IPC. 9, 10 Endotheliumtargeted overexpression of GTPCH-1 by gene transfer or pharmacological supplementation of BH 4 maintains endothelial BH 4 content and restores the ability of endothelial cells to produce NO. 9, 11 It remains unknown, however, whether the cardioprotective potential of IPC can be preserved during HG by increasing myocardial BH 4 concentrations.
Materials and methods
The experimental procedures were approved by the Animal Care and Use Committee of the Medical College of Wisconsin (Milwaukee, WI, USA) and conformed to the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996). Detailed methods are described in the Supplementary material online.
Myocardial ischaemia/reperfusion injury in vivo
Myocardial infarction was produced by occluding the left anterior descending coronary artery, as previously described.
12 -14
Experimental protocol
The effects of HG, IPC, and hyperosmolarity (HOsm) on myocardial ischaemia/reperfusion (I/R) injury were examined in C57BL/6 mice assigned to five experimental groups (7 -10 mice/group): control (CON), HG, IPC, IPC + HG, and IPC + HOsm ( Figure 1A ). All mice were stabilized for 30 min and subjected to 30 min of coronary occlusion followed by 2 h of reperfusion (I/R). IPC was elicited with four consecutive 5 min episodes of coronary occlusion, each followed by a 5 min of reperfusion. D-Glucose (2 g/kg) or mannitol (1.82 g/kg) was administered intraperitoneal 10 min before IPC to produce HG or HOsm, respectively. Tail blood was sampled at baseline, 10 min after D-glucose injection, 15 and 30 min after coronary occlusion, and 60 and 120 min after reperfusion for measurement of blood glucose concentrations (Glucometer). In separate mice, hearts were excised 5 min after reperfusion and myocardium from the area at risk (AAR) was homogenized and centrifuged at 14 000 g for 20 min at 48C. Tissue NO and its metabolite products (nitrate and nitrite) in the supernatant, collectively known as NO x , were assayed using a NO chemiluminescence analyzer (Siever 280i NO Analyzer). 15 
Generation of transgenic GTPCH-1 mice
The transgene for the a myosin heavy chain (aMHC) promoter/haemagglutinin (HA) epitope-tag/human GTPCH-1 transgene was kindly provided by Dr Nicholas Alp (University of Oxford, Oxford, UK) for generating cardiomyocyte-targeted overexpression of the human GTPCH-1 gene. 16 The transgene was comprised of the murine aMHC promoter including the first three non-translated exons; HA epitope tag; and human GTPCH-1 cDNA; human growth hormone poly A signal. The construct was generated in E. coli cultures by sub-cloning PCR-modified HA-hGTPCH cDNA from phGTPCHA + , into a Sal I restriction site in a plasmid containing the murine aMHC promoter (GenBank Accession Number U71441) within non-translated aMHC exon 3. The resulting plasmid, paMHCGTPCHA + , was confirmed by DNA sequencing using standard techniques. The human GTPCH-1 transgene was excised from paMHCGTPCHA + by NotI digestion, gel-purified, and dissolved in sterile injection buffer (5 mM Tris/Cl, pH 7.5, 0.1 mM EDTA). Oocyte microinjection of the construct was performed at the Transgenic Core Facility of the Medical College of Wisconsin and injected oocytes were transferred into pseudopregnant recipient females. Offspring were screened for genomic DNA from tail tips, using primers specific for the murine aMHC promoter sequence (P1, forward; 5 ′ -CCTTCC TCACCCCCTGGCTTGTCC-3 ′ ) and for the HA sequence (P2, reverse; 5 ′ -AGTCGGGCACGTCGTAGGGGTAGG-3 ′ ), producing a 516 bp PCR product. (A) Effects of HG, IPC, and hyperosmolarity (HOsm) on infarct size in WT mice subjected to coronary occlusion followed by reperfusion; (B) effects of overexpression of the GTP cyclohydrolase (GTPCH) 1 gene on I/R injury with or without IPC in the presence or absence of HG or L-NAME; (C) effects of GTPCH-1 overexpression on IPC-induced changes in the mitochondrial permeability transition pore (mPTP) in the presence or absence of HG and/or L-NAME.
Expression of GTPCH-1 mRNA in transgenic mice
Total cellular RNA was isolated from heart tissue and complimentary DNA was synthesized from 1 mg of total RNA, as previously described. Figure 1B) .
Transgenic (GTPCH-Tg) mice with cardiomyocyte-specific overexpression of GTPCH 1 and their wild-type (WT) littermate mice were randomly assigned to one of the six groups (n ¼ 7 -8 mice/group): CON, N G -nitro-L-arginine methyl ester (L-NAME), IPC, IPC + L-NAME, IPC + HG, IPC + HG + L-NAME. IPC and HG were produced, as described above. L-NAME, a non-selective inhibitor of NOS (1 mg/kg), was administered intraperitoneally 80 min prior to coronary artery occlusion or 40 min prior to IPC. In separate experiments, the effects of GTPCH-1 overexpression on cardiac BH 4 and NO x concentrations during IPC were examined in mice randomly assigned to the following four groups: sham, HG, IPC, and IPC + HG. Mice in sham and HG groups underwent no coronary occlusion. Cardiac BH 4 concentrations were assayed by high performance liquid chromatography, as described below.
BH 4 assay
BH 4 was quantified in left ventricular (LV) biopsies by high performance liquid chromotography with electrochemical detection, as previously described. 18 Filtrates were analysed on a high performance liquid Z.-D. Ge et al.
chromotography system (ESA Biosciences CoulArray w system, Model 582 and 542) using an analytical Polar-RP column eluted with argon saturated 50 mM phosphate buffer (pH 2.6). Authentic BH 4 solutions (10 -100 nM) were used as standards and sample concentrations were normalized to protein content measured by the bicinchoninic acid protein assay.
Transthoracic echocardiography
LV structure and function were evaluated using transthoracic echocardiography. 14 
Detection of the mitochondrial permeability transition pore opening in isolated mitochondria
GTPCH-Tg mice and WT littermates were assigned to one of the seven groups: sham, CON, L-NAME, IPC, IPC + L-NAME, IPC + HG, and IPC + HG + L-NAME ( Figure 1C ). Sham mice were not subjected to coronary occlusion. The hearts were excised after 5 min of final reperfusion, and mitochondria were isolated from the AAR. Opening of the mitochondrial permeability transition pore (mPTP) after in vitro Ca 2+ overload was assessed by following changes in the membrane potential (DC m ) using the fluorescent dye rhodamine 123 (50 nM; Invitrogen, Carlsband, CA, USA) in the presence of pyruvate and malate (5 mM). 14 
Statistical analysis
All data are expressed as mean + SEM. Statistical analysis was performed with one-way ANOVA followed by the Bonferroni post-hoc test for multiple comparisons of multiple group means or with Student's t-test for comparisons between two group means. Repeated-measures ANOVA was used to compare the differences in heart rate and blood glucose within the groups at different time points. A value of P , 0.05 was considered as statistically significant.
Results

HG inhibited IPC-elicited decreases in infarct size and increases in NO production in WT mice in vivo
Baseline blood glucose was 206 + 13 mg/dL (n ¼ 31 mice) in unfasted C57BL/6 mice. IPC, mannitol, and I/R had no effect on blood glucose concentrations. Intraperitoneal injection of D-glucose (2 g/kg) resulted in similar increases in blood glucose ( Figure 2A ) before and after myocardial I/R in WT mice with or without IPC. There were no significant differences in blood glucose concentrations among groups receiving D-glucose (n ¼ 6-9 mice/group, P . 0.05). There were no significant differences in heart rate between experimental groups ( Table 1) . AAR was not different among the five experimental groups ( Figure 2B ). IPC significantly decreased myocardial infarct size ( Figure 2C ) compared with control experiments. HG alone did not significantly alter myocardial infarct size but blocked infarct size reduction produced by IPC. IPC significantly increased NO production in myocardium ( Figure 2D ) measured after 30 min of coronary occlusion and 5 min of reperfusion compared with control hearts that were not preconditioned. HG had no effect on NO production in the absence of IPC, but reduced increases in NO produced by IPC. In contrast to the effects of HG, mannitol did not attenuate increases in NO production during IPC. All animals were subjected to 30 min of coronary occlusion followed by 2 h of reperfusion [control (CON)]. IPC was induced by four cycles of 5 min of coronary occlusion/5 min of reperfusion in the presence or absence of HG or hyperosmolarity (HOsm), as described in Figure 1A and B. There were no statistically significant difference among groups (n ¼ 6-9 mice/ group).
Cardiomyocyte-targeted overexpression of the human GTPCH-1 gene increased myocardial BH 4 content
Expression of human GTPCH-1 mRNA normalized to GAPDH was significantly increased in hearts of GTPCH-Tg mice compared with WT littermates (Figure 3 ; n ¼ 5, P , 0.05). Overexpression of the human GTPCH-1 gene did not alter expression of mouse
GTPCH-1 overexpression rescued IPC during HG via a NO-dependent mechanism
There were no significant differences in the heart rate at baseline, or during coronary occlusion and reperfusion ( Table 1) in WT littermate and transgenic mice. AAR was comparable between groups. Myocardial infarct size ( Figure 4 and Supplementary material online, Figure S1 ) was significantly decreased by IPC in WT littermates compared with control mice. IPC produced a similar degree of protection against infarction in WT and GTPCH-Tg mice. Decreases in infarct size produced by IPC alone were not altered by L-NAME in either WT or GTPCH-Tg mice. HG inhibited the protective effect of IPC in WT littermates but not in GTPCH-Tg mice. Interestingly, L-NAME blocked the beneficial effects of GTPCH-1 overexpression during IPC and HG. Echocardiography was used to examine whether cardiomyocytespecific overexpression of GTPCH-1 altered baseline cardiac function. There were no significant differences in multiple cardiac functional indices ( Table 2) , including heart rate; LV diameter in diastole and systole; fractional shortening; peak velocity of mitral E and A waves; mitral E/A ratio; isovolumic contraction time; ejection time; isovolumic relaxation time; myocardial performance index; mitral E acceleration; E wave acceleration time; mitral E deceleration; and E wave deceleration time between C57BL/6, GTPCH-Tg, and WT littermate mice. Only LV wall thickness was found to be significantly increased in GTPCH-Tg mice compared with WT mice.
HG decreased cardiac BH 4 and NO concentrations during IPC
Baseline cardiac BH 4 concentrations were significantly higher in GTPCH-Tg hearts than in WT hearts ( Figure 5A and B) . IPC increased BH 4 concentrations in WT but not GTPCH-Tg hearts. HG decreased BH 4 concentrations in GTPCH-Tg hearts and in both WT and GTPCH-Tg hearts during IPC. BH 4 concentrations were significantly higher in GTPCH-Tg hearts than in WT hearts during IPC in the presence of HG (n ¼ 5, P , 0.05).
There were no significant differences in baseline NO x concentrations between GTPCH-Tg and WT hearts ( Figure 5C and D) . HG did not change baseline NO x concentrations but decreased IPC-elicited increases in NO x production. IPC-elicited increases in NOx production were significantly higher in GTPCH-Tg hearts than in WT hearts in the presence and absence of HG (n ¼ 9, P , 0.05).
HG reduced IPC-elicited protection against mPTP opening in WT littermates but not GTPCH-Tg hearts
In the WT sham group, the concentration of in vitro Ca 2+ loading necessary to open the mPTP was 253 + 5 mmol CaCl 2 mg 21 protein (n ¼ 10). This concentration was reduced (P , 0.05) in mitochondria isolated from WT hearts subjected to I/R ( Figure 6 ). IPC significantly increased the amount of Ca 2+ required to elicit mPTP opening, indicating protection. HG abrogated the protective effect of IPC in WT littermates and increased the sensitivity of mPTP opening to CaCl 2 . In contrast, HG did not attenuate the protective effects of IPC on mPTP opening in GTPCH-Tg mice. L-NAME did not change the effects of I/R and IPC on mPTP in both WT and GTPCH-Tg mice; however, L-NAME blocked the beneficial effect of IPC on mPTP in hyperglycaemic, GTPCH-Tg mice.
Discussion
The results of the present investigation confirm and extend previous findings that HG reduce the beneficial effects of IPC to protect against myocardial infarction and inhibit mPTP opening. FMN. 24 In the presence of adequate substrate, L-arginine, and cofactor BH 4 , haem and oxygen reduction are coupled to the synthesis of NO. However, electron transfer within the active site of NOS can become uncoupled from L-arginine oxidation during conditions of low intracellular BH 4 . Thus, NOS uncoupling causes molecular oxygen to be reduced to O 2 †2 . 25 Interestingly, O 2 †2 is the sole product of recombinant eNOS in the absence of BH 4 and conversely, increases in BH 4 favour enhanced production of NO, a decrease in O 2 †2
, 26 and maintenance of eNOS in a phosphorylated active form. 20 NOS-derived NO has been shown to produce cardioprotection 27 and to be a crucial mediator of the late phase of IPC. 28 However, the role of NOS/NO in the early phase of IPC is controversial. 29 -32 In the present study, L-NAME did not block the early phase of IPC to protect against myocardial infarction in normoglycemic WT mice, in agreement with a recent study by Guo et al. in mice. 32 Brief episodes of preconditioning ischaemia and reperfusion cause the release of adenosine, opioids, bradykinin, and oxygen radicals in addition to NO, and these mediators act on multiple signalling pathways to elicit myocardial protection. 33 It is possible that redundant signalling mechanisms can compensate for a loss of NO, and thus, NO is not required to trigger protection in normal myocardium. However, L-NAME blocked the beneficial effects of GTPCH-1 overexpression during IPC and HG. HG has been demonstrated to adversely affect multiple pathways of cardioprotective signalling. 34, 35 Unlike normal myocardium, other preconditioning mediators may fail to compensate for loss of NO in hyperglycaemic myocardium. Interestingly, NO levels in GTPCH-Tg hearts during IPC and HG were maintained at levels roughly equal to the WT hearts with IPC alone. Augmented BH 4 /NO signalling by cardiomyocyte-specific overexpression of GTPCH-1 appeared to overcome the signal transduction defects induced by HG. We have previously demonstrated that diabetes and HG block infarct size reduction in response to ischaemic and pharmacological preconditioning. 3, 6, 36, 37 and that sepiapterin, a metabolic precursor of BH 4 , restores NO production during HG. 23 The current results provide critical evidence that genetic strategies designed to increase BH 4 bioavailability during HG also enhance cardioprotection. This contention is supported by other evidence that myocardial I/R injury decreases intracellular BH 4 concentrations in parallel with overproduction of O 2 †2
, 38 while in contrast, supplementation of BH 4 improves LV function after I/R. 39 Exogenous BH 4 also increases NO production and decreases O 2 †2 concentrations during conditions, such as diabetes, 40 acute HG, 41 hypercholesterolaemia, 42 and chronic smoking. 11 Interestingly, we have demonstrated that the 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor simvastatin restores IPC during HG through a NO-dependent mechanism 6 and statins have been shown to stimulate the synthesis of BH 4 by increasing the expression of GTPCH-1. 43 Taken together, the results indicate that targeting BH 4 directly with cardiomyocyte-specific overexpression of the GTPCH-1 gene, or indirectly with statins, may represent important therapeutic approaches to restoring cardioprotective signalling during diabetes and HG. Endothelium-targeted overexpression of GTPCH-1 by gene transfer has been reported to maintain endothelial BH 4 content during HG and diabetes and to restore both the activity of eNOS and endothelial-dependent relaxation. 9, 20 Our novel results indicate that cardiomyocyte-specific overexpression of this gene restores IPC during relative eNOS deficiency as observed with acute HG. In addition, overexpression of the GTPCH-1 gene and subsequently preserved BH 4 concentrations during HG may have maintained NOS in a coupled state; however, this hypothesis remains to be specifically tested. The current findings also indicate that during HG GTPCH-1 overexpression protects mitochondria against I/R injury. The importance of mitochondria as both targets and mediators of I/R injury is becoming increasingly recognized. 44 mPTP is an oxidative stress-sensitive channel involved in cell death. 45 It remains closed during myocardial ischaemia but opens during the first several minutes of reperfusion due to Ca 2+ overload and excessive production of reactive oxygen species. 45 The opening of the mPTP results in depolarization of the membrane potential and matrix swelling, which leads to rupture of the outer membrane and release of proteins such as cytochrome c from the intermembrane space into the cytosol. HG produces excessive amounts of O 2 †2 by mitochondria and favours mPTP opening and subsequent cell death. 46 IPC has previously been demonstrated to inhibit mPTP opening at reperfusion and this action appears to be a key downstream effector of IPC. 47 Although not directly established, the current results support the contention that HG may have enhanced mPTP opening, whereas overexpression of the GTPCH-1 gene restored the ability of IPC to prevent mPTP opening during HG. AWd, anterior wall (interventricular septum) at end-diastole; AWs, anterior wall at end systole; PWd, posterior wall at diastole; PWs, posterior wall at systole; LVIDd, LV internal diameter at diastole; LVIDs, LV internal diameter at systole; fractional shortening, 100 × (LVIDd-LVIDs)/LVIDd; Peak E, peak velocity of mitral E valve; Peak A, peak velocity of mitra A wave; IVCT, isovolumic contraction time of LV; IVRT, isovolumic relaxation time of LV; MPI (myocardial performance index) ¼ the ratio of the sum of isovolumic contraction and relaxation times to ejection time; Eat, mitral E wave acceleration time; Edt, E wave deceleration time. *P , 0.05 vs. C57BL/6 and WT littermates (n ¼ 10 mice/group).
The current results should be interpreted within the constraints of several potential limitations. Mannitol used as an osmolarity control is a reactive oxygen species scavenger and could contribute to cardioprotection. However, we have previously demonstrated that the nonmetabolic sugar raffinose that does not scavenger reactive oxygen species fails to block IPC, in contrast to the findings during administration of glucose. 48 In addition, BH 4 is an essential co-factor for several other enzymes, including tyrosine hydroxylase, phenylalanine hydroxylase, and tryptophan hydroxylase, and modulates the synthesis of catecholamines. It is unknown whether cardiomyocytespecific overexpression of the GTPCH-1 gene might have increased cardiac catecholamine synthesis. However, there were no changes in heart rate or echocardiographic indices of ventricular function to suggest that BH 4 -induced changes in basal catecholamine levels played a significant role in the results observed during this investigation. The results show that BH 4 levels were substantially higher in GTPCH-Tg compared with WT mice at baseline and BH 4 was not further increased by IPC. However, IPC significantly enhanced NO production during HG in GTPCH-Tg mice and NO levels were similar to that observed during IPC in WT mice. Thus, enhancing BH 4 may preserve the fidelity of NO production in response to IPC stimuli despite HG. Although L-NAME blocked the productive Cardioprotection by BH 4 during hyperglycaemia effect of GTPCH-1 overexpression, we did not directly examine the effects of L-NAME on NO production in the mice. In summary, the findings demonstrate that IPC failed to attenuate mPTP opening during HG. In contrast, cardiomyocyte-specific overexpression of the GTPCH-1 gene restored the efficacy of IPC to decrease myocardial I/R injury during HG by increasing bioavailability of BH 4 and NO, and this was blocked by NOS inhibition. Thus, genetic modulation of GTPCH-1 may represent a novel approach to the treatment of cardiovascular disease during diabetes and HG.
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